Biotech Stocks on Investors' Radar -- Aralez Pharma, Arena Pharma, Arrowhead Pharma, and AveXis
NEW YORK, Nov. 8, 2017 /PRNewswire/ -- If you want a Stock Review on ARLZ, ARNA, ARWR, or AVXS then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. On Tuesday, November 07, 2017, US markets saw five out of nine sectors finishing the day in red, three in green, and one in neutral territory. Major US indices were also mixed at the close of yesterday's session. The NASDAQ Composite ended the day at 6,767.78, down 0.27%; the Dow Jones Industrial Average edged 0.04% higher, to finish at 23,557.23; and the S&P 500 closed at 2,590.64, down 0.02%. This Wednesday morning, DailyStockTracker.com looks at the performance of these four Biotechnology stocks: Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR), and AveXis Inc. (NASDAQ: AVXS). This morning's free research reports on the aforesaid equities can be accessed upon registration on DailyStockTracker.com at:
http://dailystocktracker.com/register/
Aralez Pharmaceuticals
On Tuesday, shares in Milton, Canada headquartered Aralez Pharmaceuticals Inc. recorded a trading volume of 408,803 shares. The stock ended the session 4.26% lower at $1.80. The Company's shares have gained 60.71% over the previous three months. The stock is trading above its 50-day moving average by 9.44%. Moreover, shares of Aralez Pharma, which operates as a specialty pharmaceutical company in Canada, Ireland, and the US, have a Relative Strength Index (RSI) of 55.74. Visit us today and download your complete report on ARLZ for free at:
http://dailystocktracker.com/registration/?symbol=ARLZ
Arena Pharmaceuticals
San Diego, California-based Arena Pharmaceuticals Inc.'s stock closed the day 1.03% lower at $27.90 with a total trading volume of 607,164 shares, which was above their three months average volume of 501.89 thousand shares. The Company's shares have advanced 34.59% in the previous three months, 89.80% over the last twelve months, and 96.48% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 9.16% and 49.79%, respectively. Additionally, shares of Arena Pharma, which focuses on developing novel small molecule drugs for various therapeutic areas in the US and Switzerland, have an RSI of 60.10. The complimentary research report on ARNA can be accessed at:
http://dailystocktracker.com/registration/?symbol=ARNA
Arrowhead Pharmaceuticals
Shares in Pasadena, California headquartered Arrowhead Pharmaceuticals Inc. recorded a trading volume of 280,789 shares. The stock ended yesterday's trading session 2.72% lower at $3.57. The Company's shares have advanced 94.02% over the previous three months and 130.32% on an YTD basis. The stock is trading above its 200-day moving average by 58.42%. Furthermore, shares of Arrowhead Pharma, which develops novel drugs to treat intractable diseases in the US, have an RSI of 44.26. Register for free on DailyStockTracker.com and download the research report on ARWR at:
http://dailystocktracker.com/registration/?symbol=ARWR
AveXis
Bannockburn, Illinois headquartered AveXis Inc.'s stock finished Tuesday's session 2.48% lower at $101.87 with a total trading volume of 274,667 shares. The Company's shares have advanced 59.07% in the past twelve months and 113.43% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 4.75% and 26.14%, respectively. Additionally, shares of AveXis, which engages in developing and commercializing treatments for patients suffering from rare and life-threatening neurological genetic diseases, have an RSI of 51.73.
On October 27th, 2017, research firm Canaccord Genuity initiated a 'Hold' rating on the Company's stock, with a target price of $110 per share. Get free access to your research report on AVXS at:
http://dailystocktracker.com/registration/?symbol=AVXS
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
http://dailystocktracker.com/disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE dailystocktracker.com
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article